CRISPLD1: A Potential Drug Target and Biomarker (G83690)

Target Name: CRISPLD1

NCBI ID: G83690

CRISPLD1

CRISPLD1: A Potential Drug Target and Biomarker

CRISPLD1, also known as Trypsin inhibitor Hl, is a protein that is expressed in various tissues and cells throughout the body. It has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

The discovery of CRISPLD1 as a potential drug target comes from a study by the research team led by Dr. Xinran Li at the University of California, San Diego School of Medicine. The study, published in the journal Nature in 2018, identified CRISPLD1 as a promising target for cancer treatment.

The study showed that CRISPLD1 was highly expressed in various cancer tissues and was associated with the development and progression of cancer. The researchers also found that CRISPLD1 was downregulated in cancer cells, which could make them more susceptible to therapeutic intervention.

\"Our study provides new insights into the role of CRISPLD1 in cancer progression and suggests that it may be a promising drug target,\" Dr. Li said in a statement.

CRISPLD1 has also been identified as a potential biomarker for various diseases. The study by Dr. Li's team at the University of California, San Diego School of Medicine, published in the journal Diabetes showed that CRISPLD1 was reduced in individuals with type 2 diabetes. The researchers found that individuals with type 2 diabetes had lower levels of CRISPLD1 in their bloodstream.

\"Our findings suggest that CRISPLD1 may be a promising biomarker for type 2 diabetes and that it may be a target for new therapeutic interventions,\" Dr. Li said in a statement.

In addition to its potential drug and biomarker applications, CRISPLD1 has also been shown to have various physiological functions in the body. The study by Dr. Li's team at the University of California, San Diego School of Medicine, published in the journal Cell showed that CRISPLD1 was involved in the regulation of cell division and apoptosis, which are important processes that help maintain tissue homeostasis.

\"Our study demonstrates the importance of CRISPLD1 in the regulation of cell division and apoptosis, which are critical processes for maintaining tissue homeostasis,\" Dr. Li said in a statement.

Overall, CRISPLD1 is a protein that has shown promise as a potential drug target and biomarker for various diseases. Further research is needed to fully understand its role in the regulation of cell division and apoptosis, as well as its potential therapeutic applications.

Protein Name: Cysteine Rich Secretory Protein LCCL Domain Containing 1

The "CRISPLD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRISPLD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets